Tenpoint Therapeutics is a global, clinical-stage biotech company developing treatments to rejuvenate vision in the aging eye. Its pipeline includes treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.
Products, services, technology
Our lead asset, BRIMOCHOL™ PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia. TPT-161, a novel small molecule designed to reverse cataract formation in aging adults. TPT-005, RPE cell replacement therapy for geographic atrophy.
- http://www.tenpointtherapeutics.com
- Send an email
- Henric Bjarke
